Pharmaceuticals company Granules India announced Q1FY25 results: Revenue from Operations of Q1FY25 stood at Rs 11,799 million, a growth of 20% YoY. Revenue share from the North America increased to 74% in Q1FY25 as compared to 61% in Q1FY24. Decline in Para API and PFI sales volume and price erosion. Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished dosages contribute 14%, 10%, and 76% of revenue from operations respectively for Q1FY25. ROCE is at 19.6% as compared to 9.3% YoY. Net debt stood at Rs 7,941 million and Net debt to EBITDA at 0.77x. Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “With our robust quarterly performance, we are back on our planned trajectory after a few setbacks last year. Q1 performance highlights include continued growth in our formulation segment, strong North America business, and product diversification, which offset the Paracetamol API/PFI decline, promising a brighter future driven by our formulations offering and new product pipeline.” Result PDF
Pharmaceuticals company Granules India announced Q4FY24 results: Revenue from Operations of Q4FY24 stood at Rs 11,758 million, a decline of 2% YoY. Formulations including GPI manufactured products grew by 41%. Revenue share from the North America increased to 70% in Q4FY24 as compared to 58% in Q4FY23. Decline in Para API sales volume and price erosion. Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished dosages contribute 14%, 13%, and 73% of revenue from operations respectively for Q4FY24. ROCE is at 16.5% as compared to 21.2% YoY. Net debt stood at Rs 8,421 million and Net debt to EBITDA at 0.98x. Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We had a strong uptick in gross margin for the Q4 and for the full year, with continued growth in formulations share coming from US and Europe as part of our global expansion strategy and a higher contribution from new products. While the fiscal year numbers were below expectations due to cyber incident and low paracetamol demand, we are very excited about the way our strategies for the future are playing out and look forward to the upcoming years.” Result PDF
